In response to the global COVID-19 pandemic, the need for rapid generation of reliable evidence for safe and effective treatment is unprecedented.

Outside of clinical trials, expanded access efforts have resulted in the collection of “real world” data; which may, or may not, rise to the level of usable evidence. This webinar will bring together a panel of international experts in drug development, patient advocacy, clinical trial design, and bioethics to discuss the following: considerations when collecting data from expanded access; whether data provides robust evidence for safety and effectiveness of potential treatments for Covid-19; and the complementary role of real-world data with clinical trial-derived evidence.

REGISTRATION

REGISTER HERE (tinyurl.com/y3harxb4)
Registration: $50 (plus Eventbrite handling fee)
Student & ASLME members registration: Free
Webinar link will be sent to participants upon registration.
Continuing Legal Education (CLE) credit may be available.

Contact: Sage.Gustafson@nyulangone.org

Welcome
Ted Hutchinson, Executive Director, ASLME
Tara Sklar, JD, MPH
Director, Health Law & Policy Program, University of Arizona
James E. Rogers College of Law

Keynote Speaker
Michael Joyner, MD
Frank R. and Shari Caywood Professor of Anesthesiology,
Mayo Clinic, Principal investigator, Expanded Access to
Convalescent Plasma for the Treatment of Patients with
COVID-19

Panelists
Hayley Belli, PhD, MS
Assistant Professor in the Division of Biostatistics,
Co-Chair of Ethics & Real World Evidence Project of CUPA,
NYU Grossman School of Medicine

Holly Fernandez Lynch, JD, MBE
John Russell Dickson, MD, Presidential Assistant Professor
of Medical Ethics and Health Policy, University of
Pennsylvania

Claudia Hirawat
Owner & Executive Chair, VOZ Advisors; venture partner,
Nest Bio

Tom Watson, BSc
Executive Vice President for Early Access Programs, Bionical
Emas, Co-Chair of Ethics & Real World Evidence Project of
CUPA, NYU Grossman School of Medicine